GAL and cancer: In SK-BR-3, the GLUT receptor inhibitor (WZB117) showed significant inhibition of the Gal-PEG3-/ce6-PEG4-AuNPs interaction with this cancer cell line (Fig. S18b†); and there was no significant inhibition with the SGLT or galectin inhibitors.